載入中
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
前收盤價
US$5.67
+US$0.14 · +2.53%
盤中時間採用ET。市場資料可能有所延遲。
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
日內區間
目前US$5.67
52週區間
目前US$5.67
盤中時間採用ET。市場資料可能有所延遲。
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
日內區間
目前US$5.67
52週區間
目前US$5.67
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2542.1萬 USD | 2.11億 USD | 1.29億 USD | — | — |
| 銷貨成本 | 409.6萬 USD | — | — | — | — |
| 毛利 | 2132.5萬 USD | 2.11億 USD | 1.29億 USD | — | — |
| 研究與開發 | 1.42億 USD | 1.25億 USD | 9988.4萬 USD | 6660.9萬 USD | 3592.6萬 USD |
| 銷售、一般及管理費用 | 4105萬 USD | 3846.5萬 USD | 3229.1萬 USD | 3063.9萬 USD | 1520.1萬 USD |
| 營業費用 | 1.77億 USD | 1.64億 USD | 1.32億 USD | 9724.8萬 USD | 5112.7萬 USD |
| 利息收入 | — | 1947.4萬 USD | 1521.8萬 USD | 263.2萬 USD | — |
| 利息支出 | — | — | — | 263.2萬 USD | — |
| 折舊和攤銷 | 409.6萬 USD | 377.3萬 USD | 284.1萬 USD | 189.5萬 USD | 111.7萬 USD |
| 營業利益 | −1.56億 USD | 4701.1萬 USD | −316.2萬 USD | −9724.8萬 USD | −5112.7萬 USD |
| 淨利 | −1.44億 USD | 6562.6萬 USD | −668.5萬 USD | −9461.6萬 USD | −5115.8萬 USD |
公司資料更新於 2026年10月11日。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI672.38萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM434.02萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF199.54萬0.00%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO119.48萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Biotechnology ETFIBB102.31萬0.01%108.2億 USD0.44%US$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA79.22萬0.00%218.24億 USD0.03%US$32.79+0.40%
iShares Micro-Cap ETFIWC51.69萬0.04%13.17億 USD0.60%US$183+0.11%
Dimensional - US Small Cap ETFDFAS47.56萬0.00%338.69億 USD0.31%US$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
